AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
AccuStem Sciences (OTCQB: ACUT) has acquired the license for the proprietary microRNA Signature Classifier (MSC) test, a blood-based lung cancer screening technology. The test, developed by researchers at Istituto Nazionale Tumori (INT), evaluates 24 micro RNAs to enhance the accuracy of low-dose computed tomography (LDCT) in patients with pulmonary nodules.
Published data demonstrates that patients who test positive for both MSC and LDCT have a 30-fold higher cumulative lung cancer incidence compared to those negative for both tests. The combination of MSC with LDCT shows a five-fold reduction in false positives versus LDCT alone, potentially leading to improved outcomes and reduced healthcare costs.
The acquisition terms include issuing 3,750,000 common shares of AccuStem, with a 13-month resale restriction period. The company plans to launch the MSC test in the US in 2026.
AccuStem Sciences (OTCQB: ACUT) ha acquisito la licenza per il test proprietario del Classificatore di microRNA (MSC), una tecnologia di screening per il cancro ai polmoni basata su un esame del sangue. Il test, sviluppato da ricercatori dell'Istituto Nazionale Tumori (INT), valuta 24 micro RNA per migliorare l'accuratezza della tomografia computerizzata a bassa dose (LDCT) nei pazienti con noduli polmonari.
I dati pubblicati dimostrano che i pazienti che risultano positivi sia al MSC che al LDCT hanno un'incidenza cumulativa di cancro ai polmoni 30 volte superiore rispetto a quelli negativi per entrambi i test. La combinazione di MSC con LDCT mostra una riduzione di cinque volte dei falsi positivi rispetto al solo LDCT, portando potenzialmente a risultati migliori e a costi sanitari ridotti.
I termini dell'acquisizione includono l'emissione di 3.750.000 azioni ordinarie di AccuStem, con un periodo di restrizione alla rivendita di 13 mesi. L'azienda prevede di lanciare il test MSC negli Stati Uniti nel 2026.
AccuStem Sciences (OTCQB: ACUT) ha adquirido la licencia para el Classificador de microARN (MSC), una tecnología de detección de cáncer de pulmón basada en sangre. La prueba, desarrollada por investigadores del Instituto Nacional de Tumores (INT), evalúa 24 micro ARN para mejorar la precisión de la tomografía computarizada de baja dosis (LDCT) en pacientes con nódulos pulmonares.
Los datos publicados demuestran que los pacientes que dan positivo tanto en MSC como en LDCT tienen una incidencia acumulativa de cáncer de pulmón 30 veces mayor en comparación con aquellos negativos en ambas pruebas. La combinación de MSC con LDCT muestra una reducción de cinco veces en los falsos positivos en comparación con LDCT solo, lo que podría conducir a mejores resultados y menores costos de atención médica.
Los términos de la adquisición incluyen la emisión de 3.750.000 acciones comunes de AccuStem, con un período de restricción de reventa de 13 meses. La compañía planea lanzar la prueba MSC en EE. UU. en 2026.
AccuStem Sciences (OTCQB: ACUT)는 혈액 기반 폐암 스크리닝 기술인 마이크로RNA 서명 분류기(MSC) 테스트에 대한 라이센스를 취득했습니다. 이 테스트는 이탈리아 국가 종양 연구소(INT)의 연구원들이 개발했으며, 폐 결절이 있는 환자에서 저선량 컴퓨터 단층 촬영(LDCT)의 정확성을 향상시키기 위해 24개의 마이크로 RNA를 평가합니다.
발표된 데이터에 따르면, MSC와 LDCT 모두에서 양성 반응을 보이는 환자들은 두 테스트 모두에서 음성 반응을 보이는 환자들에 비해 폐암 발생률이 30배 더 높습니다. MSC와 LDCT의 조합은 LDCT 단독에 비해 5배 감소된 위양성률을 보여주며, 이는 더 나은 결과와 의료 비용 절감으로 이어질 수 있습니다.
인수 조건에는 3,750,000주의 AccuStem 보통주 발행이 포함되며, 13개월의 재판매 제한 기간이 있습니다. 회사는 2026년 미국에서 MSC 테스트를 출시할 계획입니다.
AccuStem Sciences (OTCQB: ACUT) a acquis la licence pour le test de Classificateur de microARN (MSC), une technologie de dépistage du cancer du poumon basée sur un test sanguin. Le test, développé par des chercheurs de l'Institut National du Cancer (INT), évalue 24 micro ARN pour améliorer la précision de la tomodensitométrie à faible dose (LDCT) chez les patients présentant des nodules pulmonaires.
Les données publiées montrent que les patients qui testent positifs à la fois pour le MSC et le LDCT ont une incidence cumulée de cancer du poumon 30 fois plus élevée par rapport à ceux qui sont négatifs aux deux tests. La combinaison de MSC avec LDCT montre une réduction de cinq fois des faux positifs par rapport à LDCT seul, ce qui pourrait conduire à de meilleurs résultats et à des coûts de santé réduits.
Les conditions de l'acquisition incluent l'émission de 3.750.000 actions ordinaires d'AccuStem, avec une période de restriction de revente de 13 mois. La société prévoit de lancer le test MSC aux États-Unis en 2026.
AccuStem Sciences (OTCQB: ACUT) hat die Lizenz für den proprietären MikroRNA-Signaturklassifizierer (MSC) erworben, eine blutbasierte Screening-Technologie für Lungenkrebs. Der Test, der von Forschern des Nationalen Krebsforschungsinstituts (INT) entwickelt wurde, bewertet 24 Mikro-RNAs, um die Genauigkeit der niedrig dosierten Computertomographie (LDCT) bei Patienten mit Lungenknoten zu verbessern.
Veröffentlichte Daten zeigen, dass Patienten, die sowohl bei MSC als auch bei LDCT positiv testen, eine kumulierte Lungenkrebs-Inzidenz von 30-fach höher haben im Vergleich zu denen, die bei beiden Tests negativ sind. Die Kombination von MSC mit LDCT zeigt eine fünfmalige Reduzierung von falsch positiven Ergebnissen im Vergleich zu LDCT allein, was potenziell zu besseren Ergebnissen und niedrigeren Gesundheitskosten führen könnte.
Die Bedingungen der Übernahme umfassen die Ausgabe von 3.750.000 Stammaktien von AccuStem, mit einer 13-monatigen Verkaufsbeschränkung. Das Unternehmen plant, den MSC-Test 2026 in den USA auf den Markt zu bringen.
- Acquisition of innovative blood-based diagnostic technology
- 30-fold higher cancer detection rate when MSC/LDCT positive
- 5x reduction in false positives compared to current standard
- Potential for significant healthcare cost reduction
- All intellectual property rights included in acquisition
- Share dilution through issuance of 3,750,000 new shares
- Extended timeline to market (launch planned for 2026)
- Currently trading on less liquid OTCQB market
- AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026
LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces the acquisition of the license for the proprietary microRNA Signature Classifier (MSC) test. The inventors of the proprietary lung cancer screening test will continue to collaborate and also provide all historic data, research and know-how relating to the Proprietary MSC Test from certain secured creditors and interest holders relating to MSC test.
The MSC test was developed by researchers Mattia Boeri, PhD, Ugo Pastorino, MD, and Gabriella Sozzi, PhD, at the Istituto Nazionale Tumori (INT) to help physicians more accurately screen patients at risk of lung cancer. The blood-based test evaluates 24 micro RNAs to improve the diagnostic performance of low-dose computed tomography (LDCT) in patients with pulmonary nodules.
“We are excited to obtain the rights to a novel test like MSC that could meaningfully benefit the millions of patients diagnosed with lung nodules each year,” said Wendy Blosser, Chief Executive Officer of AccuStem. “We believe the test will provide more definitive diagnoses and peace of mind for patients beyond LDCT screening alone, with the added benefit of saving costs to the healthcare system.”
By utilizing MSC in combination with LDCT, clinicians will be able to more accurately stratify and manage lung nodules. Data published in Annals of Oncology show that MSC+/LDCT+ patients have a cumulative lung cancer incidence 30-fold higher than MSC-/LDCT- patients whose screening intervals could be safely delayed without reducing the detection of early-stage, curable cancers. Further, analyses published in the Journal of Clinical Oncology show that combining MSC with LDCT results in a five-fold reduction in false positives compared to LDCT alone, which could lead to improved patient outcomes, fewer biopsies and lower healthcare costs.
“We are pleased to be partnering with a leadership team that has such broad experience commercializing novel, disruptive tests in the oncology space,” said Gabriella Sozzi, Director of the Research Department at INT Milan. “With the quality and quantity of data behind MSC, we believe our work together will maximize the impact of the MSC test by ensuring it is accessible to as many patients as possible.”
The consideration for the acquisition is to be satisfied by the issue of 3,750,000 common shares in the capital of AccuStem credited as fully paid (the “Consideration Shares”). The terms of the acquisition include the transfer of all rights, title and interest, in the intellectual property relating to the MSC test. The Consideration Shares are to be issued to certain secured creditors and interest holders relating to MSC test. The Consideration Shares are subject to resale restrictions for a period of 13 months from the date of closing of the acquisition.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
Forward-Looking Statements
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. AccuStem Sciences, Inc. assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contact:
Email: Info@accustem.com
Investor Contact:
Email: investors@accustem.com
FAQ
What is the expected launch date for AccuStem's (ACUT) MSC lung cancer screening test in the US?
How many AccuStem (ACUT) shares were issued for the MSC test acquisition?
What is the accuracy improvement of MSC combined with LDCT compared to LDCT alone?
How many micro RNAs does AccuStem's (ACUT) MSC test evaluate for lung cancer screening?
What is the lock-up period for the shares issued in the ACUT MSC test acquisition?
